2025-12-23 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co Inc (MRK) based on the provided data.

**1) Return Rate Comparison & Analysis**

*   **Company Overview:** Merck & Co Inc is a global pharmaceutical company focused on innovative medicines and vaccines.
*   **Cumulative Return of MRK:** 20.298%
*   **Cumulative Return of S&P 500 (VOO):** 100.884%
*   **Divergence:**
    *   **Current:** -80.6%
    *   **Relative Divergence:** 18.5%

**Analysis:** MRK has significantly underperformed the S&P 500 over the analyzed period.  The current divergence is -80.6%, a large difference, and the relative divergence of 18.5% indicates that this underperformance is closer to the lower end of its historical range compared to the S&P 500. This indicates that historically, the underperformance has sometimes been even worse than it is now.

**Alpha, Beta Analysis & CAGR, MDD:**

| Year       | CAGR   | MDD    | Alpha   | Beta  | Cap(B) |
|------------|--------|--------|---------|-------|--------|
| 2015-2017  | 1.0%   | 68.5%  | -28.0%  | 0.0   | 138.9  |
| 2016-2018  | 36.0%  | 69.8%  | 21.0%   | -0.0  | 188.7  |
| 2017-2019  | 40.0%  | 69.8%  | 18.0%   | 0.3   | 224.6  |
| 2018-2020  | 16.0%  | 79.6%  | -8.0%   | 0.3   | 202.0  |
| 2019-2021  | 2.0%   | 79.6%  | -44.0%  | 0.7   | 198.3  |
| 2020-2022  | 15.0%  | 79.6%  | 16.0%   | 0.7   | 287.1  |
| 2021-2023  | 33.0%  | 79.6%  | 31.0%   | 0.3   | 282.1  |
| 2022-2024  | -4.0%  | 79.6%  | -25.0%  | 0.2   | 257.4  |
| 2023-2025  | -29.0% | 71.5%  | -94.0%  | 1.8   | 261.6  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) fluctuates considerably. Recently, it has turned negative, indicating poor performance over the last few years.
*   **MDD:** Maximum Drawdown (MDD) is consistently high, reflecting substantial potential losses for investors.
*   **Alpha:** The Alpha values are highly variable. The recent negative Alpha indicates significant underperformance relative to its benchmark after adjusting for risk (Beta).
*   **Beta:** Beta is mostly below 1, suggesting the stock is theoretically less volatile than the market. However, the recent increase to 1.8 shows a greater correlation and amplified volatility relative to the market.
*   **Cap(B):** Market capitalization fluctuates.

**2) Recent Stock Price Fluctuations**

*   **Close:** 101.089
*   **Last Market:** Price: 104.72, Previous Close: 101.09, Change: 3.59
*   **5-day SMA:** 99.898
*   **20-day SMA:** 100.5595
*   **60-day SMA:** 91.8107

**Analysis:** The current price is above both the 5-day and 20-day Simple Moving Averages (SMAs), suggesting a short-term upward trend. The 60-day SMA is significantly lower, indicating a longer-term price trend is still upward, and also the recent upward movement. The positive change in the "Last Market" data reinforces this upward momentum.

**3) RSI, PPO, Divergence, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 50.54
*   **PPO:** -0.4883
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent (20 days) relative divergence change:** 1.3 (+)
*   **Expected Return (%):** -47.6%

**Analysis:**

*   **MRI:** Suggests a medium level of risk.
*   **RSI:** An RSI of 50.54 is neutral, neither overbought nor oversold.
*   **PPO:** A negative PPO suggests that the short-term moving average is below the long-term moving average, indicating a potential downtrend but given the RSI and short term SMA information is is more likely that this is a short term correction of the recent upwards movement.
*   **Hybrid Signal:** Recommends buying 100% of cash, suggesting that the current levels are attractive for investment.
*   **Divergence Change:** A positive change suggests the stock is starting to catch up to the S&P 500, however the positive change is minor.
*   **Expected Return:** The low/negative Expected Return indicates a very pessimistic outlook for future performance and suggests a projected underperformance compared to the S&P 500 over the next two years.

**4) Recent News & Significant Events**

*   **Positive Sentiment:** Jim Cramer stating "Merck (MRK) is an Inexpensive Stock" and articles suggesting "Merck Stock Now 2.1% Cheaper, Time To Buy" indicate positive sentiment and potential undervaluation.
*   **Trump Drug-Pricing Deal:** The news regarding drug-pricing bargains could be a double-edged sword. While it might improve affordability, it could also squeeze profit margins for Merck.
*   **Soaring Stock, Buy or Not?** This article from The Motley Fool questions whether the recent price increase is sustainable.
*   **Institutional Buying:** Brighton Jones LLC buying shares indicates institutional confidence.

**Analysis:** The news is a mix of positive and potentially negative catalysts. Analyst upgrades and bargain-hunting mentions suggest potential upside.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.90 (~Buy)
*   **Opinions:** 26
*   **Target Price (avg/high/low):** 110.04 / 139.00 / 83.00

**Analysis:** The analyst consensus is "Buy" with a mean rating close to a strong buy, suggesting a positive outlook from analysts, despite the other indicators. The average target price of $110.04 indicates an expected upside from the current price, with a high target of $139 implying significant potential growth.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출         |
|------------|------|-------------|
| 2025-11-05 | 2.32 | 17.28 B$    |
| 2025-08-05 | 1.76 | 15.81 B$    |
| 2025-05-02 | 2.01 | 15.53 B$    |
| 2024-11-06 | 1.25 | 16.66 B$    |
| 2025-11-05 | 1.25 | 16.66 B$    |

**Analysis:** EPS (Earnings Per Share) and revenue have generally increased over the recent quarters, indicating positive business growth. The most recent EPS of 2.32 is significantly higher than the previous year, suggesting improved profitability.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.28B   | 77.69%        |
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |

**Analysis:** Both revenue and profit margin are trending upwards, suggesting an improvement in the company's financial health.

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $51.85B   | 11.16%  |
| 2025-06-30   | $48.99B   | 9.04%   |
| 2025-03-31   | $48.34B   | 10.51%  |
| 2024-12-31   | $46.31B   | 8.08%   |
| 2024-09-30   | $44.50B   | 7.09%   |

**Analysis:** Equity and ROE (Return on Equity) are also showing an upward trend, demonstrating increased shareholder value and efficient use of capital.

**7) Comprehensive Analysis**

Merck (MRK) presents a mixed picture.

*   **Underperformance:**  It has significantly underperformed the S&P 500 over the analyzed period, and has experienced a high level of volatility. The negative expected return further raises concern.
*   **Technical Indicators:** Technical indicators provide a mixed outlook, with a potentially short-term upwards trend.
*   **Analyst Optimism:**  Despite the underperformance, analysts maintain a "Buy" rating.
*   **Recent Performance:** Recent quarterly results are positive, showing improving revenue, profit margins, and ROE.
*   **News Sentiment:** Recent news suggests some positive sentiment and undervaluation opportunities.

**Overall Recommendation:**

The investment recommendation is highly uncertain.

*   **Potential Buy:**  The analyst consensus, potential undervaluation, and recent improvements in financial performance suggest it might be a turnaround opportunity. The Hybrid Signal supports buying.
*   **Potential Sell/Hold:**  The significant underperformance, negative expected return, high MDD, and recent negative Alpha should be carefully considered.

**Recommendation:** Given these factors, the investment decision should be based on individual risk tolerance and investment horizon.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.